(Total Views: 205)
Posted On: 01/24/2022 2:35:28 PM
Post# of 250662
$QNTA trading low volume with little BID support in spite of the great News last week...
Medolife Rx, Inc. ("Medolife"
, a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that the Company submitted the final clinical trial data to the Dominican Republic (“DR”) Ministry of Health (“MoH”) for approval of the Company’s product, Escozine, as a COVID-19 treatment. The product, which is registered as an alternative oncological medicine in the DR, has shown to be effective against variations of the SARS-CoV-2 virus.
Medolife Rx, Inc. ("Medolife"
, a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that the Company submitted the final clinical trial data to the Dominican Republic (“DR”) Ministry of Health (“MoH”) for approval of the Company’s product, Escozine, as a COVID-19 treatment. The product, which is registered as an alternative oncological medicine in the DR, has shown to be effective against variations of the SARS-CoV-2 virus.
(0)
(0)
